Alex Y. C. Chang

555 total citations
27 papers, 437 citations indexed

About

Alex Y. C. Chang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alex Y. C. Chang has authored 27 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alex Y. C. Chang's work include Cancer Treatment and Pharmacology (7 papers), Lung Cancer Research Studies (7 papers) and Cancer therapeutics and mechanisms (7 papers). Alex Y. C. Chang is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Lung Cancer Research Studies (7 papers) and Cancer therapeutics and mechanisms (7 papers). Alex Y. C. Chang collaborates with scholars based in United States, Singapore and Macao. Alex Y. C. Chang's co-authors include Peter C. Keng, John M. Bennett, P. A. Bourne, P.C. Keng, D C Tormey, Jiangbin Wu, Athanasios Mantalaris, Raman Qazi, Charles L. Loprinzi and H. C. Falkson and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Alex Y. C. Chang

27 papers receiving 420 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alex Y. C. Chang United States 11 177 133 93 65 56 27 437
Guy Rosner Israel 13 220 1.2× 155 1.2× 97 1.0× 67 1.0× 61 1.1× 24 587
L Anselmi Italy 7 188 1.1× 87 0.7× 81 0.9× 103 1.6× 33 0.6× 17 354
Susan B. Ingersoll United States 8 144 0.8× 144 1.1× 55 0.6× 67 1.0× 33 0.6× 21 516
V. Barbounis Greece 15 231 1.3× 102 0.8× 115 1.2× 85 1.3× 71 1.3× 31 481
Jelena Urosevic Spain 8 227 1.3× 221 1.7× 72 0.8× 111 1.7× 34 0.6× 10 462
Yasuo Kodera Japan 8 167 0.9× 167 1.3× 120 1.3× 64 1.0× 34 0.6× 14 405
David L. Doering United States 13 125 0.7× 137 1.0× 54 0.6× 107 1.6× 29 0.5× 21 503
Eiji Kawamura Japan 10 132 0.7× 92 0.7× 54 0.6× 30 0.5× 35 0.6× 26 386
Dimitrios Tryfonopoulos Greece 12 269 1.5× 176 1.3× 96 1.0× 119 1.8× 55 1.0× 46 627
Katsuyuki Kunieda Japan 13 288 1.6× 198 1.5× 164 1.8× 79 1.2× 81 1.4× 83 697

Countries citing papers authored by Alex Y. C. Chang

Since Specialization
Citations

This map shows the geographic impact of Alex Y. C. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Y. C. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Y. C. Chang more than expected).

Fields of papers citing papers by Alex Y. C. Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Y. C. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Y. C. Chang. The network helps show where Alex Y. C. Chang may publish in the future.

Co-authorship network of co-authors of Alex Y. C. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Y. C. Chang. A scholar is included among the top collaborators of Alex Y. C. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Y. C. Chang. Alex Y. C. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Qi, et al.. (2019). Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy. Molecular Pharmaceutics. 16(9). 3873–3886. 4 indexed citations
2.
3.
Mantalaris, Athanasios, P.C. Keng, P. A. Bourne, Alex Y. C. Chang, & Jiangbin Wu. (1998). Engineering a Human Bone Marrow Model: A Case Study on ex Vivo Erythropoiesis. Biotechnology Progress. 14(1). 126–133. 49 indexed citations
4.
Chang, Alex Y. C., KyungMann Kim, Philip Bonomi, et al.. (1998). A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma. Cancer. 82(2). 292–300. 39 indexed citations
5.
Cristofanilli, Massimo, William J. Bryan, Langdon L. Miller, et al.. (1998). Phase II study of adozelesin in untreated metastatic breast cancer. Anti-Cancer Drugs. 9(9). 779–782. 30 indexed citations
6.
Chang, Alex Y. C., et al.. (1997). Pharmacokinetics of intrapericardial administration of 5-fluorouracil. Cancer Chemotherapy and Pharmacology. 40(4). 318–320. 13 indexed citations
7.
Chang, Alex Y. C., Russell F. DeVore, Cindy Gu, Peter Keng, & Robert F. Asbury. (1997). In Vitro and Clinical Studies: Paclitaxel and Vinorelbine in Non-Small-Cell Lung Cancer. 11. 31–34. 2 indexed citations
8.
Chang, Alex Y. C., Cindy Gu, Robert F. Asbury, Russell F. DeVore, & Peter Keng. (1997). PACLITAXEL AND VINORELBINE IN NON-SMALL-CELL LUNG CANCER. 11(10). 31–34. 5 indexed citations
9.
Chang, Alex Y. C., Z. Nora Tu, Julia Smith, et al.. (1995). Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. Investigational New Drugs. 13(2). 137–141. 8 indexed citations
10.
Flores, J F, et al.. (1994). Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer. 73(10). 2527–2534. 9 indexed citations
11.
Chang, Alex Y. C., et al.. (1991). Nasopharyngeal Carcinoma in Young Patients. American Journal of Clinical Oncology. 14(1). 1–4. 1 indexed citations
12.
Chang, Alex Y. C., J. McL. Bennett, Kishan J. Pandya, Robert F. Asbury, & Craig S. McCune. (1989). A Study of Aminoglutethemide and Hydrocortisone in Patients with Advanced and Refractory Prostate Carcinoma. American Journal of Clinical Oncology. 12(4). 358–360. 9 indexed citations
13.
Rowe, Jacob M., Alex Y. C. Chang, & John M. Bennett. (1989). Refractory acute lymphocytic leukemia: Response to aclacinomycin a and VP‐16‐213. Hematological Oncology. 7(6). 405–410. 5 indexed citations
14.
Ettinger, David S., Dianne M. Finkelstein, Ross C. Donehower, et al.. (1989). Phase II study of N‐methylformamide, spirogermanium, and 4‐demethoxydaunorubicin in the treatment of non‐small cell lung cancer (EST 3583): An Eastern cooperative oncology group study. Medical and Pediatric Oncology. 17(3). 197–201. 13 indexed citations
15.
Qazi, Raman, Alex Y. C. Chang, Richard F. Borch, et al.. (1988). Phase I Clinical and Pharmacokinetic Study of Diethyldithiocarbamate as a Chemoprotector From Toxic Effects of Cisplatin. JNCI Journal of the National Cancer Institute. 80(18). 1486–1488. 51 indexed citations
16.
Chang, Alex Y. C. & Peter C. Keng. (1987). Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle.. PubMed. 47(16). 4338–41. 64 indexed citations
17.
Cave, William T., et al.. (1987). Adrenal Insufficiency. Journal of Clinical Gastroenterology. 9(4). 470–474. 19 indexed citations
18.
Pandya, Kishan J., et al.. (1986). Combination Chemotherapy for Advanced Colorectal Cancer A Pilot Study. American Journal of Clinical Oncology. 9(1). 31–34. 7 indexed citations
19.
Chang, Alex Y. C. & Peter C. Keng. (1983). Inhibition of Cell Growth in Synchronous Human Hypernephroma Cells by Recombinant Interferon Alpha-D and Irradiation. Journal of Interferon Research. 3(4). 379–385. 11 indexed citations
20.
Witte, Robert S., Alex Y. C. Chang, & D C Tormey. (1982). Vindesine sulfate (VND): A phase II trial in small cell bronchogenic carcinoma (SCCL). 1. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guy Rosner Breakdown of academic impact, for papers by L Anselmi Breakdown of academic impact, for papers by Susan B. Ingersoll Breakdown of academic impact, for papers by V. Barbounis Breakdown of academic impact, for papers by Jelena Urosevic Breakdown of academic impact, for papers by Yasuo Kodera Breakdown of academic impact, for papers by David L. Doering Breakdown of academic impact, for papers by Eiji Kawamura Breakdown of academic impact, for papers by Dimitrios Tryfonopoulos Breakdown of academic impact, for papers by Katsuyuki Kunieda
Rankless by CCL
2026